ANCA-associated vasculitides-advances in pathogenesis and treatment

Nature Reviews Rheumatology

Volumn 6, Issue 11, 2010, Pages 653-664

  Chen, Min ^a   Kallenberg, Cees G M ^b  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5A RECEPTOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; HYDRALAZINE; IMMUNOGLOBULIN; INTERLEUKIN 17; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PENICILLAMINE; PREDNISOLONE; PROPYLTHIOURACIL; RITUXIMAB; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; B LYMPHOCYTE; BACTERIAL INFECTION; BLADDER CARCINOMA; BONE MARROW SUPPRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; DUST EXPOSURE; HEMORRHAGIC CYSTITIS; HEREDITY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INNATE IMMUNITY; LEUKOPENIA; LIVER DYSFUNCTION; LYMPHOCYTE COUNT; MICROSCOPIC POLYANGIITIS; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RENOVASCULAR DISEASE; REVIEW; RISK FACTOR; SERUM SICKNESS; SOLID TUMOR; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS;

ANIMALS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; GLUCOCORTICOIDS; HUMANS; METHOTREXATE; MICE; REMISSION INDUCTION;

EID: 78049530106     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.158     Document Type: Review

References (120)

1. Jennette, J. C. et al. Nomenclature of systemic vasculitides: the proposal of an international consensus conference. Arthritis Rheum. 37, 187-192 (1994).
2. Watts, R. et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann. Rheum. Dis. 66, 222-227 (2007).
3. Liu, L. J., Chen, M., Yu, F., Zhao, M. H. & Wang, H. Y. Evaluation of a new algorithm in classification of systemic vasculitis. Rheumatology (Oxford) 47, 708-712 (2008).
4. American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) diagnostic and classification criteria for primary systemic vasculitis (DCVAS). ClinicalTrials.gov identifier: NCT01066208 [online], http://clinicaltrials.gov/ct2/show/NCT01066208 (2010).
5. Jagiello, P., Gross, W. L. & Epplen, J. T. Complex genetics of Wegener granulomatosis. Autoimmun. Rev. 4, 42-47 (2005).
6. de Lind van Wijngaarden, R. A. et al. Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: the cause is hidden, but the result is known. Clin. J. Am. Soc. Nephrol. 3, 237-252 (2008).
7. Shiina, T., Inoko, H. & Kulski, J. K. An update of the HLA genomic region, locus information and disease associations: 2004. Tissue Antigens 64, 631-649 (2004).
8. Heckmann, M. et al. The Wegener's granulomatosis quantitative trait locus on chromosome 6p21.3 as characterised by tagSNI genotyping. Ann. Rheum. Dis. 67, 972-979 (2008).
9. Stassen, P. M. et al. HLA-DR4, DR13 (6) and the ancestral haplotype A1B8DR3 are associated with ANCA-associated vasculitis and Wegener's granulomatosis. Rheumatology (Oxford) 48, 622-625 (2009).
10. Vaglio, A. et al. HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum. 56, 3159-3166 (2007).
11. *0901 with microscopic polyangiitis. J. Rheumatol. 30, 1534-1540 (2003).
12. Wieczorek, S. et al. Novel association of the CD226 (DNAM-1) Gly307Ser polymorphism in Wegener's granulomatosis and confirmation for multiple sclerosis in German patients. Genes lmmun. 10, 591-595 (2009).
13. Carr, E. J. et al. Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis. BMC Med. Genet. 10, 121 (2009).
14. Wieczorek, S. et al. Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibodynegative Churg-Strauss syndrome, but not with Wegener's granulomatosis. Arthritis Rheum. 58, 1839-1848 (2008).
15. McKinney, E. F. et al. A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat. Med. 16, 586-591 (2010).
16. Hogan, S. L. et al. Silica exposure in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis. J. Am. Soc. Nephrol. 12, 134-142 (2001).
17. Beaudreuil, S. et al. Occupational exposure in ANCA-positive patients: a case-control study. Kidney Int. 67, 1961-1966 (2005).
18. Leigh, J., Wang, H., Bonin, A., Ieters, M. & Ruan, X. Silica-induced apoptosis in alveolar and granulomatous cells in vivo. Environ. Health Perspect. 105 (Suppl. 5), 1241-1245 (1997).
19. Aikoh, T. et al. Activation-induced cell death in human peripheral blood lymphocytes after stimulation with silicate in vitro. Int. J. Oncol. 12, 1355-1359 (1998).
20. Stegeman, C. A., Tervaert, J. W., de Jong, P. E. & Kallenberg, C. G. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N. Engl. J. Med. 335, 16-20 (1996).
21. Stegeman, C. A. et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann. Intern. Med. 120, 12-17 (1994).
22. Iopa, E. R. et al., Staphylococcal toxic-shocksyndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology (Oxford) 46, 1029-1033 (2007).
23. Popa, E. R., Stegeman, C. A., Kallenberg, C. G. & Tervaert, J. W. Staphylococcus aureus and Wegener's granulomatosis. Arthritis Res. 4, 77-79 (2002).
24. rd et al. Autoimmunity is triggered by cPR-3 (105-201), a protein complementary to human autoantigen proteinase-3. Nat. Med. 10, 72-79 (2004).
25. Kallenberg, C. G. & Tadema, H. Vasculitis and infections: contribution to the issue of autoimmunity reviews devoted to "autoimmunity and infection". Autoimmun. Rev. 8, 29-32 (2008).
26. Hurtado, P. R. et al. CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis. BMC Immunol. 9, 34 (2008).
27. Kain, R. et al. A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells. J. Exp. Med. 181, 585-597 (1995).
28. Kain, R. et al. Molecular mimicry in pauciimmune focal necrotizing glomerulonephritis. Nat. Med. 14, 1088-1096 (2008).
29. Slot, M. C., Links, T. P, Stegeman, C. A. & Tervaert, J. W. Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: a long-term followup study. Arthritis Rheum. 53, 108-113 (2005).
30. Zhao, M. H., Chen, M., Gao, Y. & Wang, H. Y. Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 69, 1477-1481 (2006).
31. Lee, E. et al. Inactivation of peroxidases of rat bone marrow by repeated administration of propylthiouracil is accompanied by a change in the heme structure. Biochem. Pharmacol. 37, 2151-2153 (1988).
32. Jiang, X., Khursigara, G. & Rubin, R. L. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science 266, 810-813 (1994).
33. von Schmiedeberg S., Goebel, C., Gleichmann, E. & Uetrecht, J. Neutrophils and drug metabolism. Science 268, 585-586 (1995).
34. Gilligan, H. M. et al. Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. J. Exp. Med. 184, 2231-2241 (1996).
35. Csernok, E., Lamprecht, P. & Gross, W. L. Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidaseantineutrophil cytoplasmic antibodies and vasculitis. Curr. Opin. Rheumatol. 22, 43-48 (2010).
36. Davies, D. J., Moran, J. E., Niall, J. F. & Ryan, G. B. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus etiology? Br. Med. J. (Clin. Res. Ed.) 285, 606 (1982).
37. Bansal, P. J. & Tobin, M. C. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann. Allergy Asthma Immunol. 93, 398-401 (2004).
38. Falk, R. J., Nachman, I. P. H., Hogan, S. L. & Jennette, J. C. ANCA glomerulonephritis and vasculitis: a Chapel Hill perspective. Semin. Nephrol. 20, 233-243 (2000).
39. Savage, C. O. ANCA-associated renal vasculitis. Kidney Int. 60, 1614-1627 (2001).
40. Boomsma, M. M. et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 43, 2025-2033 (2000).
41. Stegeman, C. A. Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis. Nephrol. Dial. Transplant. 17, 2077-2080 (2002).
42. Birck, R., Schmitt, W. H., Kaelsch, I. A. & van der Woude, F. J. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am. J. Kidney Dis. 47, 15-23 (2006).
43. Kerr, G. S. et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum. 36, 365-371 (1993).
44. Finkielman, J. D. et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann. Intern. Med. 147, 611-619 (2007).
45. Falk, R. J., Terrell R. S., Charles, L. A. & Jennette, J. C. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals. Proc. Natl Acad. Sci. USA 87, 4115-4119 (1990).
46. Schreiber, A., Busjahn, A., Luft, F. C. & Kettritz, R. Membrane expression of proteinase 3 is genetically determined. J. Am. Soc. Nephrol. 14, 68-75 (2003).
47. van Rossum, A. P. et al. Standardised assessment of membrane proteinase 3 expression. Analysis in ANCA-associated vasculitis and controls. Ann. Rheum. Dis. 66, 1350-1355 (2007).
48. Witko-Sarsat, V. et al. A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis. J. Am. Soc. Nephrol. 10, 1224-1233 (1999).
49. Rarok, A. A., Stegeman, C. A., Limburg, P. C. & Kallenberg, C. G. Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J. Am. Soc. Nephrol. 13, 2232-2238 (2002).
50. Bauer, S. et al. Proteinase 3 and CD177 are expressed on the plasma membrane of the same subset of neutrophils. J. Leukoc. Biol. 81, 458-464 (2007).
51. von Vietinghoff, S. et al. NB1 mediates surface expression of the ANCA antigen proteinase 3 on human neutrophils. Blood 109, 4487-4493 (2007).
52. Hu, N. et al. Coexpression of CD177 and membrane proteinase 3 on neutrophils in antineutrophil cytoplasmic autoantibody associated systemic vasculitis, anti-proteinase 3-mediated neutrophil activation is independent of the role of CD177-expressing neutrophils. Arthritis Rheum. 60, 1548-1557 (2009).
53. Hess, C., Sadallah, S. & Schifferli, J. A. Induction of neutrophil responsiveness to myeloperoxidase antibodies by their exposure to supernatant of degranulated autologous neutrophils. Blood 96, 2822-2827 (2000).
54. Guilpain, P et al. Pathogenic effects of antimyeloperoxidase antibodies in patients with microscopic polyangiitis. Arthritis Rheum. 56, 2455-2463 (2007).
55. Xiao, H. et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 110, 955-963 (2002).
56. Huugen, D. et al. Aggravation of antimyeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am. J. Pathol. 167, 47-58 (2005).
57. Schreiber, A., Xiao, H., Falk, R. J. & Jennette, J. C. Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies. J. Am. Soc. Nephrol. 17, 3355-3364 (2006).
58. Pfister, H. et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 104, 1411-1418 (2004).
59. van der Geld, Y. M. et al. Rats and mice immunised with chimeric human/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes. Ann. Rheum. Dis. 66, 1679-1682 (2007).
60. Little, M. A. et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 106, 2050-2058 (2005).
61. Nolan, S. L. et al. Mechanisms of ANCA-mediated leukocyte-endothelial cell interactions in vivo. J. Am. Soc. Nephrol. 19, 973-984 (2008).
62. Xiao, H. et al. The role of neutrophils in the induction of glomerulonephritis by antimyeloperoxidase antibodies. Am. J. Pathol. 167, 39-45 (2005).
63. Chen, M., Wang, F. & Zhao, M. H. Circulating neutrophil gelatinase-associated lipocalin: a useful biomarker for assessing disease activity of ANCA-associated vasculitis. Rheumatology (Oxford) 48, 355-358 (2009).
64. Kessenbrock, K. et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat. Med. 15, 623-625 (2009).
65. Chen, M. & Kallenberg, C. G. Novel territory for neutrophils in the pathogenesis of ANCA-associated vasculitides. Nephrol. Dial. Transplant. 24, 3618-3620 (2009).
66. Van Timmeren, M. M., Chen, M. & Heeringa, P. Review article: pathogenic role of complement activation in anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. Nephrology (Carlton) 14, 16-25 (2009).
67. Chen, M., Xing, G. Q., Yu, F., Liu, G. & Zhao, M. H. Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis. Nephrol. Dial. Transplant. 24, 1247-1252 (2009).
68. Xing, G. Q. et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J. Clin. Immunol. 29, 282-291 (2009).
69. Xiao, H., Schreiber, A., Heeringa, P., Falk, R. J. & Jennette, J. C. Alternative complement pathway in the pathogenesis of disease mediated by antineutrophil cytoplasmic autoantibodies. Am. J. Pathol. 170, 52-64 (2007).
70. Huugen, D. et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int. 71, 646-654 (2007).
71. Schreiber, A. et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J. Am. Soc. Nephrol. 20, 289-298 (2009).
72. Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221-232 (2010).
73. Jones, R. B. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363, 211-220 (2010).
74. Shlomchik, M. J., Craft, J. E. & Mamula, M. J. From T to B and back again: positive feedback in systemic autoimmune disease. Nat. Rev. Immunol. 1, 147-153 (2001).
75. Voswinkel, J. et al. B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann. Rheum. Dis. 65, 859-864 (2006).
76. Brouwer, E. et al. Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders. Clin. Exp. Immunol. 83, 379-386 (1991).
77. Schmitt, W. H. et al. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. 65, 1440-1448 (2004).
78. Berden, A. E. et al. Cellular immunity in Wegener's granulomatosis: characterizing T lymphocytes. Arthritis Rheum. 60, 1578-1587 (2009).
79. Müller, A. et al. Localized Wegener's granulomatosis: predominance of CD26 and IFNgamma expression. J. Pathol. 192, 113-120 (2000).
80. Lamprecht, P. et al. Differences in CCR5 expression on peripheral blood CD4+CD28-T-cells and in granulomatous lesions between localized and generalized Wegener's granulomatosis. Clin. Immunol. 108, 1-7 (2003).
81. Sanders, J. S., Stegeman, C. A. & Kallenberg, C. G. The Th1 and Th2 paradigm in ANCA-associated vasculitis. Kidney Blood Press. Res. 26, 215-220 (2003).
82. Jin, D., Zhang, L., Zheng, J. & Zhao, Y. The inflammatory Th 17 subset in immunity against self and non-self antigens. Autoimmunity 41, 154-162 (2008).
83. Abdulahad, W. H., Stegeman, C. A., Limburg, P. C. & Kallenberg, C. G. Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. Arthritis Rheum. 58, 2196-2205 (2008).
84. Nogueira, E. et al. Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol. Dial. Transplant. 25, 2209-2217 (2010).
85. + T cell subpopulations in ANCA-associated vasculitis. Clin. Exp. Immunol. 140, 181-191 (2005).
86. Iking-Konert, C. et al. T lymphocytes in patients with primary vasculitis: expansion of CD8+ T cells with the propensity to activate polymorphonuclear neutrophils. Rheumatology (Oxford) 47, 609-616 (2008).
87. Abdulahad, W. H., van der Geld, Y. M., Stegeman, C. A. & Kallenberg, C. G. Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis. Kidney Int. 70, 938-947 (2006).
88. Abdulahad, W. H., Kallenberg, C. G., Limburg, P. C. & Stegeman, C. A. Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum. 60, 2830-2838 (2009).
89. Abdulahad, W. H. et al. Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission. Arthritis Rheum. 56, 2080-2091 (2007).
90. Morgan, M. D. et al. Patients with Wegener's granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells. Immunology 130, 64-73 (2010).
91. Chavele, K. M. et al. Regulation of myeloperoxidase-specific T cell responses during disease remission in antineutrophil cytoplasmic antibody-associated vasculitis: the role of Treg cells and tryptophan degradation. Arthritis Rheum. 62, 1539-1548 (2010).
92. Hoffman, G. S. et al. Wegener granulomatosis: an analysis of 158 patients. Ann. Intern. Med. 116, 488-498 (1992).
93. Jayne, D. R. & Rasmussen, N. Treatment of antineutrophil cytoplasm autoantibodyassociated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin. Proc. 72, 737-747 (1997).
94. Guillevin, L. et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum. 40, 2187-2198 (1997).
95. Talar-Williams, C. et al. Cyclophosphamideinduced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann. Intern. Med. 124, 477-484 (1996).
96. De Groot, K. et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52, 2461-2469 (2005).
97. Mukhtyar, C. et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann. Rheum. Dis. 68, 310-317 (2009).
98. Adu, D. et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 90, 401-409 (1997).
99. Guillevin, L. et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum. 40, 2187-2198 (1997).
100. de Groot, K. et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann. Intern. Med. 150, 670-680 (2009).
101. Smith, K. G., Jones, R. B., Burns, S. M. & Jayne, D. R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 54, 2970-2982 (2006).
102. Jones, R. B. et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 60, 2156-2168 (2009).
103. Keogh, K. A. et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am. J. Respir. Crit. Care Med. 173, 180-187 (2006).
104. Keogh, K. A., Wylam, M. E., Stone, J. H. & Specks, U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum. 52, 262-268 (2005).
105. Stasi, R. et al. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 45, 1432-1436 (2006).
106. Jayne, D. R. et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 18, 2180-2188 (2007).
107. de Lind van Wijngaarden, R. A. et al. Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. J. Am. Soc. Nephrol. 18, 2189-2197 (2007).
108. Wegener's Granulomatosis Etanercept Trial (WGET) research group. Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 352, 351-361 (2005).
109. Clinical trial of mycophenolate versus cyclophosphamide in ANCA vasculitis. ClinicalTrials.gov identifier: NCT00414128 [online], http://clinicaltrials.gov/ct2/show/NCT00414128 (2010).
110. Hogan, S. L. et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann. Intern. Med. 143, 621-631 (2005).
111. Koldingsnes, W. & Nossent, H. Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology (Oxford) 41, 572-581 (2002).
112. Jayne, D. et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 349, 36-44 (2003). (Pubitemid 36765101)
113. Pagnoux, C. et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N. Engl. J. Med. 359, 2790-2803 (2008).
114. Metzler, C. et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 46, 1087-1091 (2007).
115. Silva, F. et al. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement-a prospective, open-label pilot trial. Clin. J. Am. Soc. Nephrol. 5, 445-453 (2010).
116. IMPROVE: Mycophenolate mofetil versus azathioprine for maintenance therapy in ANCA associated systemic vasculitis. ClinicalTrials.gov identifier: NCT00307645 [online], http://clinicaltrials.gov/ct2/show/NCT00307645 (2010).
117. Booth, A. et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 15, 717-721 (2004).
118. Flossmann, O. et al. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann. Rheum. Dis. 68, 1125-1130 (2009).
119. Schmitt, W. H. et al. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. 65, 1440-1448 (2004).
120. Prevention of relapses in proteinase 3 (PR3) - anti-neutrophil cytoplasmic antibodies (ANCA) - associated vasculitis. ClinicalTrials.gov identifier: NCT00128895 [online], http://clinicaltrials.gov/ct2/show/NCT00128895 (2010).